Lower respiratory tract infection

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, COPD, Blood, International, Chronic obstructive pulmonary disease, Bromide, Common, Headache, Nose, Cough, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, Wheeze, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Brineura, cerliponase alfa, Date of authorisation: 30/05/2017, Revision: 7, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Patient, Brain damage, Medical Subject Headings, Marketing, Traffic barrier, European Commission, Agency, INN, Risk, Fever, Lower respiratory tract infection, Metabolism, Infection, Movement, Allergy, ATC, International, European, Spinal cord, Disease, Nose, Language, Brain, Pharyngitis, Skull, Hypersensitivity, European Medicines Agency, TPP1, Select, CLN2, Safety, Anatomy, Medicine, Vomiting, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Brineura, cerliponase alfa, Date of authorisation: 30/05/2017, Revision: 7, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Brineura, cerliponase alfa, Date of authorisation: 30/05/2017, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Medical Subject Headings, Marketing, Protein, Agency, Pharyngitis, INN, ATC, Urinary tract infection, International, Cough, Cystic fibrosis, Sore throat, Ageing, Language, Literature, Pseudomonas aeruginosa, Catherine Disher, Lower respiratory tract infection, European Medicines Agency, Infection, Fibrosis, Select, Patient, Bacteria, Anatomy, IIA, Periodic breathing, Medical device

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Liver, Marketing, MP, Heart, MRI, INN, Risk, MTX, Pneumonia, Fungus, AZA, UC, Eating, Inflammation, Ankylosing spondylitis, Infection, Fungal infection, Diagnosis, Anatomy, Ulcer, Lymphoma, IIA, Skin, Vasculitis, Yeast, Psoriasis, ATC, Joint, Pain, Psoriatic arthritis, Syringe, Disease, Nose, Allergy, Lower respiratory tract infection, Nonsteroidal anti-inflammatory drug, Hepatitis B virus, Safety, Heart failure, CRP, Disorder, Rheumatoid arthritis, Sepsis, Magnetic resonance imaging, Leukemia, Patient, Medical Subject Headings, Walking, Immune system, Ulcerative colitis, International, Arthritis, Language, Blood, Hepatitis B, Medication package insert, Tuberculosis, Select, Medicine, Methotrexate, Azathioprine, TNF, X-ray, Mercaptopurine, European Medicines Agency, Spine, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Urine, Medical Subject Headings, Marketing, Protein, Acetylcholine receptor, Autoantibody, INN, GMG, Immune system, Fatigue, Lower respiratory tract infection, Infection, ATC, Antibody, International, Disease, Nose, Language, Blood, Muscle weakness, Urinary tract infection, Medicine, B cell, Neonatal Fc receptor, European Medicines Agency, Acetylcholine, Select, Patient, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Atmosphere, Patient, Medical Subject Headings, Quality of life, Fluticasone, Marketing, Sinusitis, Agency, INN, Fever, Lower respiratory tract infection, Immunoglobulin E, Allergy, ATC, Chronic pain, Pain, International, Headache, Ageing, Nose, Blood, Language, MITES, Pharyngitis, Swelling, Inflammation, Dizziness, Red, European Medicines Agency, Polyp (medicine), Select, Overalls, Anatomy, Arthralgia, IIA, Pollen, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Janus, Patient, Medical Subject Headings, Marketing, Cytokine, Protein, Human, INN, Infection, ATC, Pharyngitis, International, Nose, Language, Mouth, CPU socket, Inflammation, JAK, European Medicines Agency, Lower respiratory tract infection, PASI, Tablet, Select, Cell, Diagnosis, Janus kinase, TYK2, Anatomy, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

LEO Pharma Inc. Announces U.S. FDA approval of Adbry® (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years

Retrieved on: 
Freitag, Dezember 15, 2023
FDA, Health, Consumer, Teens, Pharmaceutical, Biotechnology, Adolescence, Lower respiratory tract infection, Safety, Food, Ageing, Incidence, IGA, Disease, Clinical trial, Patient, NRS, Conjunctivitis, EVP, Atopic dermatitis, LEO, Diagnosis, Skin, Leo Pharma, Pharmaceutical industry, Nursing, Generic drug, Tralokinumab, Northwestern University

This critical patient group now has access to a much-needed additional treatment option to manage their atopic dermatitis," said Brian Hilberdink, EVP and President, Region North America, LEO Pharma, “We are delighted to be able to offer Adbry, a highly targeted treatment, to both adult and pediatric patients in the U.S.

Key Points: 
  • This critical patient group now has access to a much-needed additional treatment option to manage their atopic dermatitis," said Brian Hilberdink, EVP and President, Region North America, LEO Pharma, “We are delighted to be able to offer Adbry, a highly targeted treatment, to both adult and pediatric patients in the U.S.
  • *1
    The approval is based on data from the Phase 3 ECZTRA 6 trial, which evaluated the efficacy and safety of Adbry in 289 pediatric patients aged 12-17 years with moderate-to-severe AD who were candidates for systemic therapy.
  • A total of 98 patients received an initial dose of Adbry 300 mg followed by 150 mg every other week up to Week 16.
  • “Such advances in the atopic dermatitis treatment landscape provide much-needed hope for pediatric patients seeking a long-term treatment option that could work for them.”
    Dr. Paller is an ECZTRA 6 clinical trial investigator and a paid consultant of LEO Pharma Inc.

"Anti-Choke Mug" - Chula Innovation for Neuro Patients to Drink Water Confidently

Retrieved on: 
Mittwoch, November 29, 2023
Parkinson's disease, Cough, Meal, Neck, Brain, Research, Esophagus, Chin, Pneumonia, Eating, Choking, Head, Food, Risk, Nose, Abdomen, Tremor, Disease, King Chulalongkorn Memorial Hospital, Sepsis, Patient, Muscular system, Lower respiratory tract infection, Alzheimer's disease, Drinking water, Spasm, Dysphagia, Urinary tract infection, Muscle weakness, Caregiver, Bacteria, Water, Alcohol, Drinking, 7th Floor, Saliva, Mouth, Trachea, Thai Red Cross Society, Quality of life, Stroke, Fever, Arteriosclerosis, Hospital, DSM-IV codes, HNRNPH2-related disorders, Habit, Pharmaceutical industry, Residential care, Electric battery, Beer

Choking in these patients can cause pneumonia, lung infections, sepsis, and eventually death, so it should not be overlooked by patients and caregivers.

Key Points: 
  • Choking in these patients can cause pneumonia, lung infections, sepsis, and eventually death, so it should not be overlooked by patients and caregivers.
  • "One of the problems for the elderly is incomplete swallowing, and there is some food residue remaining in the oral cavity.
  • Ensure that the patient is mindful of eating and drinking water, concentrating on eating and swallowing all the food.
  • Anti-choke mugs – help ease swallowing, reducing the chance of choking
    As behavioral changes for swallowing is difficult for both patients and caregivers, the research team then developed an "anti-choke mug" to help patients drink water safely.

"Anti-Choke Mug" - Chula Innovation for Neuro Patients to Drink Water Confidently

Retrieved on: 
Mittwoch, November 29, 2023
Parkinson's disease, Cough, Meal, Neck, Brain, Research, Esophagus, Chin, Pneumonia, Eating, Choking, Head, Food, Risk, Nose, Abdomen, Tremor, Disease, King Chulalongkorn Memorial Hospital, Sepsis, Patient, Muscular system, Lower respiratory tract infection, Alzheimer's disease, Drinking water, Spasm, Dysphagia, Urinary tract infection, Muscle weakness, Caregiver, Bacteria, Water, Alcohol, Drinking, 7th Floor, Saliva, Mouth, Trachea, Thai Red Cross Society, Quality of life, Stroke, Fever, Arteriosclerosis, Hospital, DSM-IV codes, HNRNPH2-related disorders, Habit, Pharmaceutical industry, Residential care, Electric battery, Beer

Choking in these patients can cause pneumonia, lung infections, sepsis, and eventually death, so it should not be overlooked by patients and caregivers.

Key Points: 
  • Choking in these patients can cause pneumonia, lung infections, sepsis, and eventually death, so it should not be overlooked by patients and caregivers.
  • "One of the problems for the elderly is incomplete swallowing, and there is some food residue remaining in the oral cavity.
  • Ensure that the patient is mindful of eating and drinking water, concentrating on eating and swallowing all the food.
  • Anti-choke mugs – help ease swallowing, reducing the chance of choking
    As behavioral changes for swallowing is difficult for both patients and caregivers, the research team then developed an "anti-choke mug" to help patients drink water safely.